Abstract
Metabolic-associated fatty liver disease (MAFLD) is defined as fat accumulation in the liver in the presence of metabolic alterations. This disorder is generally asymptomatic and may progress to severe liver disease, which are linked to inflammation and/or fibrosis. MAFLD has a high prevalence (26%) and therefore a considerable number of patients are at high risk of having advanced liver disease. This document provides an overview of the most relevant serological markers in the characterization and diagnosis of MAFLD. An example is provided of a routine diagnostic algorithm that incorporates serological testing. A range of useful serological scores are currently available for the management of MAFLD patients, especially for the stratification of patients at risk of fibrosis. A large proportion of thepopulation is at risk of developing severe liver disease. The integration of non-invasive serological markers in thestratification of patients at risk for liver fibrosis may contribute to improve the control and management of MAFLD patients.
Highlights
Guidelines and RecommendationsGuerra-Ruiz*, Gregori Casals, Paula Iruzubieta, Marta Lalana, Alba Leis, Rosa María López, Javier Crespo and Manuel Morales-Ruiz
This document provides an overview of the most relevant serological markers in the characterization and diagnosis of Metabolic-associated fatty liver disease (MAFLD)
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease (NAFLD) [1] encompasses a wide spectrum of liver lesions associated with the accumulation of fat in the liver, which is known as steatosis
Summary
Guerra-Ruiz*, Gregori Casals, Paula Iruzubieta, Marta Lalana, Alba Leis, Rosa María López, Javier Crespo and Manuel Morales-Ruiz.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have